C Nieder1,2, M Hintz3, A L Grosu3. 1. Department of Oncology and Palliative Medicine, Nordland Hospital, 8092, Bodø, Norway. carsten.nieder@nlsh.no. 2. Faculty of Health Sciences, Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway. carsten.nieder@nlsh.no. 3. Department of Radiation Oncology, University Hospital Freiburg, Freiburg, Germany.
Abstract
BACKGROUND: Treatment concepts for metastatic colorectal cancer continue to evolve. While the presence of RAS mutations impacts systemic therapy, little is known about the influence of such mutations in patients with brain metastases. PATIENTS AND METHODS: Pooled retrospective analysis was conducted of 57 patients with brain metastases from colorectal cancer treated in two different institutions (2005-2013). RESULTS: The only mutations analyzed in a relatively large subgroup were KRAS mutations (14 wild type, 12 mutated). Mutation status was not associated with baseline characteristics such as number or location of metastases, and did not impact prognosis. Three factors were significantly associated with survival in multivariate analysis: Karnofsky Performance Status (KPS), management strategy, and systemic treatment. Median survival was 0.6 months with best supportive care, 3.0 months with initial whole-brain radiotherapy (WBRT), and 12.7 months if initial treatment included surgery or stereotactic radiosurgery (SRS), p = 0.0001. The survival difference between the WBRT and surgery/SRS groups was largest in patients with KPS 80-100. CONCLUSION: Effective local treatment was a prerequisite for improved survival. The only significant prognostic baseline factor was KPS, which forms the basis of the diagnosis-specific graded prognostic assessment (DS-GPA) score. Thus, our results validate the DS-GPA in this patient population. So far, neither this nor other studies suggest a clinically important impact of KRAS mutations beyond their previously reported association with development of brain metastases. Studies focusing on patients who develop brain metastases early during the course of metastatic disease might be warranted, because the influence of different systemic therapies might be larger in this subgroup.
BACKGROUND: Treatment concepts for metastatic colorectal cancer continue to evolve. While the presence of RAS mutations impacts systemic therapy, little is known about the influence of such mutations in patients with brain metastases. PATIENTS AND METHODS: Pooled retrospective analysis was conducted of 57 patients with brain metastases from colorectal cancer treated in two different institutions (2005-2013). RESULTS: The only mutations analyzed in a relatively large subgroup were KRAS mutations (14 wild type, 12 mutated). Mutation status was not associated with baseline characteristics such as number or location of metastases, and did not impact prognosis. Three factors were significantly associated with survival in multivariate analysis: Karnofsky Performance Status (KPS), management strategy, and systemic treatment. Median survival was 0.6 months with best supportive care, 3.0 months with initial whole-brain radiotherapy (WBRT), and 12.7 months if initial treatment included surgery or stereotactic radiosurgery (SRS), p = 0.0001. The survival difference between the WBRT and surgery/SRS groups was largest in patients with KPS 80-100. CONCLUSION: Effective local treatment was a prerequisite for improved survival. The only significant prognostic baseline factor was KPS, which forms the basis of the diagnosis-specific graded prognostic assessment (DS-GPA) score. Thus, our results validate the DS-GPA in this patient population. So far, neither this nor other studies suggest a clinically important impact of KRAS mutations beyond their previously reported association with development of brain metastases. Studies focusing on patients who develop brain metastases early during the course of metastatic disease might be warranted, because the influence of different systemic therapies might be larger in this subgroup.
Authors: Roel C J Schlijper; Janneke P C Grutters; Ruud Houben; Anne-Marie C Dingemans; Joachim E Wildberger; Dirk Van Raemdonck; Eric Van Cutsem; Karin Haustermans; Guido Lammering; Philippe Lambin; Dirk De Ruysscher Journal: Cancer Treat Rev Date: 2013-06-13 Impact factor: 12.111
Authors: Elena Magni; Luigi Santoro; Paola S Ravenda; Maria C Leonardi; Guido Bonomo; Lorenzo Monfardini; Franco Nolè; Maria G Zampino Journal: Int J Colorectal Dis Date: 2013-10-26 Impact factor: 2.571
Authors: Rona Yaeger; Elizabeth Cowell; Joanne F Chou; Alexandra N Gewirtz; Laetitia Borsu; Efsevia Vakiani; David B Solit; Neal Rosen; Marinela Capanu; Marc Ladanyi; Nancy Kemeny Journal: Cancer Date: 2014-12-09 Impact factor: 6.860
Authors: Giuseppe Aprile; Elisa Zanon; Francesco Tuniz; Emiliana Iaiza; Federica De Pauli; Nicoletta Pella; Stefano Pizzolitto; Alberto Buffoli; Andrea Piga; Miran Skrap; Gianpiero Fasola Journal: J Cancer Res Clin Oncol Date: 2008-09-09 Impact factor: 4.553
Authors: Luis Del Carpio Huerta; Anna Cristina Virgili Manrique; Justyna Szafranska; Marta Martin-Richard; David Paez Lopez-Bravo; Ana Sebio Garcia; Iñigo Espinosa Mariscal; Paula Gomila Pons; Marta Andres Granyo; Andres Barba Joaquin; Agusti Barnadas Molins; Maria Tobeña Puyal Journal: Int J Colorectal Dis Date: 2018-06-25 Impact factor: 2.571
Authors: Asimina Koulouridi; Michaela Karagianni; Ippokratis Messaritakis; Maria Sfakianaki; Alexandra Voutsina; Maria Trypaki; Maria Bachlitzanaki; Evangelos Koustas; Michalis V Karamouzis; Anastasios Ntavatzikos; Anna Koumarianou; Nikolaos Androulakis; Dimitrios Mavroudis; Maria Tzardi; John Souglakos Journal: Cancers (Basel) Date: 2022-07-07 Impact factor: 6.575